- Conditions
- Atrial Fibrillation
- Interventions
- Intervention, Control
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 132
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure, Coronary Artery Disease
- Interventions
- Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 5,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 115
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more
- Conditions
- Acute Kidney Injury
- Interventions
- Not listed
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- GCC-4401C, Rivaroxaban, Placebo
- Drug
- Lead sponsor
- Green Cross Corporation
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Early Phase Clinical Unit _Los Angeles, California
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
- Interventions
- Direct Oral Anticoagulants
- Drug
- Lead sponsor
- University of Malta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Interventions
- Rivaroxaban, Warfarin and Enoxaparin
- Drug
- Lead sponsor
- Cook County Health
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pulmonary Embolism
- Interventions
- FlowTriever System, Anticoagulation Agents
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
- Conditions
- Covid19
- Interventions
- Enoxaparin, Rivaroxaban
- Drug
- Lead sponsor
- St. David's HealthCare
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Stroke
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 7,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
- Interventions
- ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
- Conditions
- Radial Artery Occlusion
- Interventions
- Rivaroxaban 15 MG Oral Tablet [Xarelto]
- Drug
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
- Interventions
- DOAC, Aspirin
- Drug
- Lead sponsor
- Kansas City Heart Rhythm Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more
- Conditions
- Venous Thrombosis
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
- Conditions
- Atrial Fibrillation (AF), VTE
- Interventions
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Other
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Atrial Fibrillation (AF), Stroke
- Interventions
- Abelacimab, Rivaroxaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more
- Conditions
- Atrial Fibrillation
- Interventions
- Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42,534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
- Interventions
- Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 151
- States / cities
- Chula Vista, California • Fremont, California • Fresno, California + 104 more
- Conditions
- Non-Valvular Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
- Interventions
- Anticoagulants
- Drug
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
- Interventions
- Acetylsalicylic acid, Clopidogrel, Rivaroxaban
- Drug
- Lead sponsor
- ECRI bv
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Pulmonary Embolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more